All News

A genomic test capable of predicting the probability of developing metastatic prostate cancer outperformed existing clinical risk factors for predicting biochemical failure and distant metastasis following radiation therapy, researchers reported at the Genitourinary Cancers Symposium in San Francisco.

The androgen-receptor blocker enzalutamide (XTANDI) increases survival by 29% in men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of the disease by 81%, according to new phase III study results in men who had not previously received chemotherapy.

Mayo Clinic researchers have found amplification of HER2, a known driver of some breast cancers, in micropapillary urothelial carcinoma and have shown that the presence of HER2 amplification is associated with particularly aggressive tumors.

The AUA announced the 2014 Urology Residency Match results last week, reporting that of medical students who submitted preference lists, 64% matched.

There is no evidence that vasectomy leads to significant health problems, making it unlikely that the Urology Nevada patient who took the life of one urologist and injured another was suffering from the effects of “botched” surgery, say two urologists who are experts in vasectomy.

In men with nonobstructive azoospermia, frozen and fresh testicular sperm offer similar fertilization and pregnancy rates, according to the authors of a meta-analysis who say it is the first such study to specifically address the fresh-versus-frozen debate in this population.

Men who walked at a fast pace prior to prostate cancer diagnosis had more regularly shaped blood vessels in their prostate tumors compared with men who walked slowly, providing a potential explanation for why exercise is linked to improved outcomes for men with prostate cancer.

Patients with chronic kidney disease who undergo robot-assisted partial nephrectomy for kidney cancer have minimal loss of renal function-a smaller amount even than patients with normal kidney function, according to researchers at Henry Ford Hospital in Detroit, who say their study is the largest of its kind.

Type of surgical approach-open or robot assisted-appears to have no effect on specific clinical outcomes in patients undergoing radical prostatectomy for high-risk prostate cancer, nor does the procedure influence the pathway subsequent therapy might follow, according to a recent study.

Results from a survey of members of the Society of University Urologists (SUU) highlight the current work force shortage in academic urology and provide information that is instructive for both academicians and urologists-in-training who are planning their career, said Joshua Langston, MD, at the 2013 American College of Surgeons Clinical Congress in Washington.

Urologist Daniel Shames, MD, has had a unique and varied career, with stops in clinical practice, the FDA, and his current role as a consultant to the pharmaceutical industry. Dr. Shames’ wide-ranging experience brings an insightful perspective on the topics he discusses in this interview: what goes into FDA drug approvals, quality of life endpoints, and the Sunshine Act.

I certainly applaud the authors’ efforts and feel that such standardized algorithms can be very beneficial for practicing urologists. However, their study lacks an objective measure of pain (such as a Likert pain score) or explanation of why many of the patients did require narcotics.